Withholding Stereotactic Radiotherapy in Elderly Patients with Stage I Non-small Cell Lung Cancer and Co-existing COPD is not Justified: Outcomes of a Markov Model Analysis

Prognostic Value of Pretreatment Circulating Neutrophils, Monocytes, and Lymphocytes on Outcomes in Lung Stereotactic Body Radiotherapy

“…Consideration of comorbid diseases such as chronic obstructive pulmonary disease (copd) is as relevant as tumour factors are in clinical decision-making for this patient population. The evidence suggests that withholding sbrt from elderly patients with advanced copd is not justified 12 and that there is no known lower limit for pulmonary function 13 . In the context of patients with previous copd diagnoses undergoing sbrt in increasing numbers, the implications of nlr and mlr in chronic disease are as important as are their roles in cancer prognosis.…”

SABR in NSCLC – The beginning of the end or the end of the beginning?

“…However, despite the apparently successful use in patients with poor lung function [21] and the theoretical benefit suggested in elderly patients [30], it remains to be shown that SABR in elderly patients with early stage NSCLC and multiple comorbidities improves survival. Careful evaluation of causes of death and the development of prognostic and predictive indices should allow for better patient selection reserving SABR for those most likely to benefit from it.…”

Stereotactic radiotherapy for early lung cancer: Evidence-based approach and future directions

“…In contrast, patients with treated T1 and T2 tumors were predicted to have a 7-48% five-year OS, depending on COPD GOLD status. 8 …”

“…SBRT differs from older techniques (termed in a small number of fractions (often [3][4][5][6][7][8], while allowing for doses in the center of the tumor that often exceed the prescription dose by 30% or more. 1 These factors, taken together, allow for the precise delivery of potent radiotherapy doses while minimizing dose to normal tissues.…”